Angiogenesis in gynecological oncology - Mechanism of tumor progression and therapeutic targets

K. K. Rasila, R. A. Burger, Harriet O. Smith, F. C. Lee, Claire Verschraegen

Research output: Contribution to journalArticle

61 Citations (Scopus)

Abstract

The purpose of this article is to review the current literature pertaining to various angiogenic stimulators and angiogenesis inhibitors in gynecological malignancies and the relevance of these markers in the prognosis of these diseases. We also summarize the antiangiogenic drugs currently in development and in clinical use in gynecological oncology. The information was obtained from a computer search of MEDLINE for studies published in the English language regarding angiogenesis and angiogenesis inhibitors in gynecological malignancies between 1970 and December 2003; additional sources were identified through cross-referencing. In ovarian cancer, various different angiogenic activators have been found to correlate with microvessed density (MVD), stage, lymph node and peritoneal metastasis, and survival. In cervical cancer, correlation has been seen between increased angiogenic markers and stage, grade, tumor size, and survival. Studies in endometriat cancer show correlation of angiogenic markers with stage, grade, MVD, and survival. Whereas, in gestational trophoblastic neoplasm (GTD) only few markers have been studied, and some correlated with progression. Information on anti angiogenic drugs currently in ongoing and upcoming trials in gynecological malignancies is also presented. Angiogenesis factors may have a prognostic role to play in patients with gynecological cancers and should continue to be investigated as clinically useful tumor markers. Antiangiogenic-targeted therapies offer an attractive strategy for clinical investigation in gynecologic oncology.

Original languageEnglish (US)
Pages (from-to)710-726
Number of pages17
JournalInternational Journal of Gynecological Cancer
Volume15
Issue number5
DOIs
StatePublished - Sep 2005
Externally publishedYes

Fingerprint

Angiogenesis Inhibitors
Neoplasms
Survival
Therapeutics
Gestational Trophoblastic Disease
Angiogenesis Inducing Agents
Tumor Biomarkers
MEDLINE
Uterine Cervical Neoplasms
Ovarian Neoplasms
Language
Lymph Nodes
Neoplasm Metastasis
Pharmaceutical Preparations

Keywords

  • Anti angiogenic durgs
  • Biologic agents
  • Female neoplasms

ASJC Scopus subject areas

  • Obstetrics and Gynecology
  • Oncology
  • Cancer Research

Cite this

Angiogenesis in gynecological oncology - Mechanism of tumor progression and therapeutic targets. / Rasila, K. K.; Burger, R. A.; Smith, Harriet O.; Lee, F. C.; Verschraegen, Claire.

In: International Journal of Gynecological Cancer, Vol. 15, No. 5, 09.2005, p. 710-726.

Research output: Contribution to journalArticle

Rasila, K. K. ; Burger, R. A. ; Smith, Harriet O. ; Lee, F. C. ; Verschraegen, Claire. / Angiogenesis in gynecological oncology - Mechanism of tumor progression and therapeutic targets. In: International Journal of Gynecological Cancer. 2005 ; Vol. 15, No. 5. pp. 710-726.
@article{62581f940e34461f8d6a473ee1221517,
title = "Angiogenesis in gynecological oncology - Mechanism of tumor progression and therapeutic targets",
abstract = "The purpose of this article is to review the current literature pertaining to various angiogenic stimulators and angiogenesis inhibitors in gynecological malignancies and the relevance of these markers in the prognosis of these diseases. We also summarize the antiangiogenic drugs currently in development and in clinical use in gynecological oncology. The information was obtained from a computer search of MEDLINE for studies published in the English language regarding angiogenesis and angiogenesis inhibitors in gynecological malignancies between 1970 and December 2003; additional sources were identified through cross-referencing. In ovarian cancer, various different angiogenic activators have been found to correlate with microvessed density (MVD), stage, lymph node and peritoneal metastasis, and survival. In cervical cancer, correlation has been seen between increased angiogenic markers and stage, grade, tumor size, and survival. Studies in endometriat cancer show correlation of angiogenic markers with stage, grade, MVD, and survival. Whereas, in gestational trophoblastic neoplasm (GTD) only few markers have been studied, and some correlated with progression. Information on anti angiogenic drugs currently in ongoing and upcoming trials in gynecological malignancies is also presented. Angiogenesis factors may have a prognostic role to play in patients with gynecological cancers and should continue to be investigated as clinically useful tumor markers. Antiangiogenic-targeted therapies offer an attractive strategy for clinical investigation in gynecologic oncology.",
keywords = "Anti angiogenic durgs, Biologic agents, Female neoplasms",
author = "Rasila, {K. K.} and Burger, {R. A.} and Smith, {Harriet O.} and Lee, {F. C.} and Claire Verschraegen",
year = "2005",
month = "9",
doi = "10.1111/j.1525-1438.2005.00132.x",
language = "English (US)",
volume = "15",
pages = "710--726",
journal = "International Journal of Gynecological Cancer",
issn = "1048-891X",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Angiogenesis in gynecological oncology - Mechanism of tumor progression and therapeutic targets

AU - Rasila, K. K.

AU - Burger, R. A.

AU - Smith, Harriet O.

AU - Lee, F. C.

AU - Verschraegen, Claire

PY - 2005/9

Y1 - 2005/9

N2 - The purpose of this article is to review the current literature pertaining to various angiogenic stimulators and angiogenesis inhibitors in gynecological malignancies and the relevance of these markers in the prognosis of these diseases. We also summarize the antiangiogenic drugs currently in development and in clinical use in gynecological oncology. The information was obtained from a computer search of MEDLINE for studies published in the English language regarding angiogenesis and angiogenesis inhibitors in gynecological malignancies between 1970 and December 2003; additional sources were identified through cross-referencing. In ovarian cancer, various different angiogenic activators have been found to correlate with microvessed density (MVD), stage, lymph node and peritoneal metastasis, and survival. In cervical cancer, correlation has been seen between increased angiogenic markers and stage, grade, tumor size, and survival. Studies in endometriat cancer show correlation of angiogenic markers with stage, grade, MVD, and survival. Whereas, in gestational trophoblastic neoplasm (GTD) only few markers have been studied, and some correlated with progression. Information on anti angiogenic drugs currently in ongoing and upcoming trials in gynecological malignancies is also presented. Angiogenesis factors may have a prognostic role to play in patients with gynecological cancers and should continue to be investigated as clinically useful tumor markers. Antiangiogenic-targeted therapies offer an attractive strategy for clinical investigation in gynecologic oncology.

AB - The purpose of this article is to review the current literature pertaining to various angiogenic stimulators and angiogenesis inhibitors in gynecological malignancies and the relevance of these markers in the prognosis of these diseases. We also summarize the antiangiogenic drugs currently in development and in clinical use in gynecological oncology. The information was obtained from a computer search of MEDLINE for studies published in the English language regarding angiogenesis and angiogenesis inhibitors in gynecological malignancies between 1970 and December 2003; additional sources were identified through cross-referencing. In ovarian cancer, various different angiogenic activators have been found to correlate with microvessed density (MVD), stage, lymph node and peritoneal metastasis, and survival. In cervical cancer, correlation has been seen between increased angiogenic markers and stage, grade, tumor size, and survival. Studies in endometriat cancer show correlation of angiogenic markers with stage, grade, MVD, and survival. Whereas, in gestational trophoblastic neoplasm (GTD) only few markers have been studied, and some correlated with progression. Information on anti angiogenic drugs currently in ongoing and upcoming trials in gynecological malignancies is also presented. Angiogenesis factors may have a prognostic role to play in patients with gynecological cancers and should continue to be investigated as clinically useful tumor markers. Antiangiogenic-targeted therapies offer an attractive strategy for clinical investigation in gynecologic oncology.

KW - Anti angiogenic durgs

KW - Biologic agents

KW - Female neoplasms

UR - http://www.scopus.com/inward/record.url?scp=28944440951&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=28944440951&partnerID=8YFLogxK

U2 - 10.1111/j.1525-1438.2005.00132.x

DO - 10.1111/j.1525-1438.2005.00132.x

M3 - Article

VL - 15

SP - 710

EP - 726

JO - International Journal of Gynecological Cancer

JF - International Journal of Gynecological Cancer

SN - 1048-891X

IS - 5

ER -